• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Hahn Mark W sold $12,000 worth of Ordinary Shares (2,400 units at $5.00), decreasing direct ownership by 0.02% to 14,288,936 units (SEC Form 4)

    11/26/24 6:36:50 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRNA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hahn Mark W

    (Last) (First) (Middle)
    3 MORE LONDON
    RIVERSIDE

    (Street)
    LONDON X0 SE1 2RE

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Verona Pharma plc [ VRNA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    11/25/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares(1) 11/25/2024 S(2) 1,600 D $5 14,289,736 D
    Ordinary Shares(1) 11/26/2024 S(2) 800 D $5 14,288,936(3) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
    2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 6, 2024.
    3. Consists of (i) 3,000,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 375,000 ADSs); and (ii) 11,288,936 Ordinary Shares underlying 1,411,117 ADSs.
    /s/ Andrew Fisher, Attorney-in-Fact for Mark Hahn 11/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRNA

    DatePrice TargetRatingAnalyst
    4/28/2025$100.00Buy
    TD Cowen
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    1/10/2025$68.00Buy
    ROTH MKM
    10/3/2024$50.00Overweight
    Wells Fargo
    5/22/2023$35.00 → $38.00Buy
    Jefferies
    9/19/2022$27.00Outperform
    Wedbush
    8/26/2022$31.00Overweight
    Piper Sandler
    11/12/2021$18.00 → $23.00Buy
    Canaccord Genuity
    More analyst ratings

    $VRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/18/24 4:20:05 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:57:21 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:56:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

      Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ("COPD"), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference ("ATS") 2025. The posters are published on the ATS website an

      5/6/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

      4/15/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    SEC Filings

    See more
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/2/25 4:24:30 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/2/25 4:24:08 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      4/29/25 4:21:40 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Financials

    Live finance-specific insights

    See more
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

      4/15/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide

      2/27/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

      ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E

      4/29/21 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 5:46:11 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:50:28 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verona Pharma plc

      SC 13G - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:31:56 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Rickard Kathleen A. sold $1,014,343 worth of Ordinary Shares (114,984 units at $8.82), decreasing direct ownership by 4% to 2,546,472 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/8/25 4:30:16 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Rickard Kathleen A. sold $440,350 worth of Ordinary Shares (49,200 units at $8.95) and converted options into 50,000 units of Ordinary Shares, increasing direct ownership by 0.03% to 2,661,456 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/5/25 4:32:18 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Hahn Mark W sold $5,311,479 worth of Ordinary Shares (587,008 units at $9.05) and converted options into 200,000 units of Ordinary Shares, decreasing direct ownership by 3% to 13,078,992 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/5/25 4:31:33 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Verona Pharma with a new price target

      TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00

      4/28/25 8:38:21 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Verona Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $80.00

      4/21/25 8:39:43 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Verona Pharma with a new price target

      ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00

      1/10/25 8:44:57 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care